Literature DB >> 21975929

Chemotherapy enhances metastasis formation via VEGFR-1-expressing endothelial cells.

Laura G M Daenen1, Jeanine M L Roodhart, Miranda van Amersfoort, Mantre Dehnad, Wijnand Roessingh, Laurien H Ulfman, Patrick W B Derksen, Emile E Voest.   

Abstract

Recent studies suggest that chemotherapy, in addition to its cytotoxic effects on tumor cells, can induce a cascade of host events to support tumor growth and spread. Here, we used an experimental pulmonary metastasis model to investigate the role of this host response in metastasis formation. Mice were pretreated with chemotherapy and after clearance of the drugs from circulation, tumor cells were administered intravenously to study potential "protumorigenic" host effects of chemotherapy. Pretreatment with the commonly used chemotherapeutic agents cisplatin and paclitaxel significantly enhanced lung metastasis in this model. This corresponded to enhanced adhesion of tumor cells to an endothelial cell monolayer that had been pretreated with chemotherapy in vitro. Interestingly, chemotherapy exposure enhanced the expression of VEGF receptor 1 (VEGFR-1) on endothelial cells both in vitro and in vivo. Administration of antibodies targeting VEGFR-1 reversed the early retention of tumor cells in the lungs, thereby preventing the formation of chemotherapy-induced pulmonary metastases. The data indicate that chemotherapy-induced expression of VEGFR-1 on endothelial cells can create an environment favorable to tumor cell homing. Inhibition of VEGFR-1 function may therefore be used to counteract chemotherapy-induced retention of tumor cells within the metastatic niche, providing a novel level of tumor control in chemotherapy. ©2011 AACR

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975929     DOI: 10.1158/0008-5472.CAN-11-0627

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  63 in total

1.  Selective Imaging of VEGFR-1 and VEGFR-2 Using 89Zr-Labeled Single-Chain VEGF Mutants.

Authors:  Jan-Philip Meyer; Kimberly J Edwards; Paul Kozlowski; Marina V Backer; Joseph M Backer; Jason S Lewis
Journal:  J Nucl Med       Date:  2016-07-07       Impact factor: 10.057

2.  Targeting Pancreatic Cancer Metastasis by Inhibition of Vav1, a Driver of Tumor Cell Invasion.

Authors:  Gina L Razidlo; Christopher Magnine; Arthur C Sletten; Rachel M Hurley; Luciana L Almada; Martin E Fernandez-Zapico; Baoan Ji; Mark A McNiven
Journal:  Cancer Res       Date:  2015-05-14       Impact factor: 12.701

Review 3.  The Role of TLR4 in Chemotherapy-Driven Metastasis.

Authors:  Sophia Ran
Journal:  Cancer Res       Date:  2015-05-21       Impact factor: 12.701

4.  2012 European thyroid association guidelines for metastatic medullary thyroid cancer urge restrained use of novel kinase inhibitors.

Authors:  Richard T Kloos
Journal:  Eur Thyroid J       Date:  2012-04

5.  Paclitaxel therapy promotes breast cancer metastasis in a TLR4-dependent manner.

Authors:  Lisa Volk-Draper; Kelly Hall; Caitlin Griggs; Sandeep Rajput; Pascaline Kohio; David DeNardo; Sophia Ran
Journal:  Cancer Res       Date:  2014-10-01       Impact factor: 12.701

6.  Heparanase and Chemotherapy Synergize to Drive Macrophage Activation and Enhance Tumor Growth.

Authors:  Udayan Bhattacharya; Lilach Gutter-Kapon; Tal Kan; Ilanit Boyango; Uri Barash; Shi-Ming Yang; JingJing Liu; Miriam Gross-Cohen; Ralph D Sanderson; Yuval Shaked; Neta Ilan; Israel Vlodavsky
Journal:  Cancer Res       Date:  2019-11-05       Impact factor: 12.701

Review 7.  Chemotherapy-induced metastasis: mechanisms and translational opportunities.

Authors:  George S Karagiannis; John S Condeelis; Maja H Oktay
Journal:  Clin Exp Metastasis       Date:  2018-01-06       Impact factor: 5.150

8.  Stress-inducible gene Atf3 in the noncancer host cells contributes to chemotherapy-exacerbated breast cancer metastasis.

Authors:  Yi Seok Chang; Swati P Jalgaonkar; Justin D Middleton; Tsonwin Hai
Journal:  Proc Natl Acad Sci U S A       Date:  2017-08-07       Impact factor: 11.205

9.  Neuroblastoma chemotherapy can be augmented by immunotargeting O-acetyl-GD2 tumor-associated ganglioside.

Authors:  S Faraj; M Bahri; S Fougeray; A El Roz; J Fleurence; J Véziers; M D Leclair; E Thébaud; F Paris; S Birklé
Journal:  Oncoimmunology       Date:  2017-09-21       Impact factor: 8.110

10.  Dual Programmed Death Receptor-1 and Vascular Endothelial Growth Factor Receptor-2 Blockade Promotes Vascular Normalization and Enhances Antitumor Immune Responses in Hepatocellular Carcinoma.

Authors:  Kohei Shigeta; Meenal Datta; Tai Hato; Shuji Kitahara; Ivy X Chen; Aya Matsui; Hiroto Kikuchi; Emilie Mamessier; Shuichi Aoki; Rakesh R Ramjiawan; Hiroki Ochiai; Nabeel Bardeesy; Peigen Huang; Mark Cobbold; Andrew X Zhu; Rakesh K Jain; Dan G Duda
Journal:  Hepatology       Date:  2019-10-14       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.